Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users). In this multicenter international registry all consecutive diabetic AMI patients undergoing percutane...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pharmacological research Ročník 187; s. 106597
Hlavní autori:	Paolisso, Pasquale, Bergamaschi, Luca, Gragnano, Felice, Gallinoro, Emanuele, Cesaro, Arturo, Sardu, Celestino, Mileva, Niya, Foà, Alberto, Armillotta, Matteo, Sansonetti, Angelo, Amicone, Sara, Impellizzeri, Andrea, Esposito, Giuseppe, Morici, Nuccia, Andrea, Oreglia Jacopo, Casella, Gianni, Mauro, Ciro, Vassilev, Dobrin, Galie, Nazzareno, Santulli, Gaetano, Marfella, Raffaele, Calabrò, Paolo, Pizzi, Carmine, Barbato, Emanuele
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier Ltd 01.01.2023
Predmet:	Acute Kidney Injury - etiology Acute myocardial infarction Arrhythmias Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy HF hospitalization Humans Myocardial Infarction - drug therapy Outcomes Percutaneous Coronary Intervention - adverse effects Registries Risk Factors SGLT2-I Sodium-Glucose Transporter 2 Inhibitors - adverse effects Treatment Outcome NSTEMI T2DM HF hospitalization Outcomes SGLT2-I OAD PCI STEMI CABG Acute myocardial infarction AMI HF Arrhythmias RWMA
ISSN:	1043-6618, 1096-1186, 1096-1186
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users). In this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. The primary endpoint was defined as a composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE). Secondary outcomes included i) in-hospital cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI); ii) long-term cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization. The study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p < 0.05). During a median follow-up of 24 ± 13 months, the primary composite endpoint, as well as cardiovascular mortality and HF hospitalization were lower for SGLT2-I users compared to non-SGLT2-I patients (p < 0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of reduced MACE occurrence (HR=0.57; 95%CI:0.33–0.99; p = 0.039) and HF hospitalization (HR=0.46; 95%CI:0.21–0.98; p = 0.041). In T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI. Data are part of the observational international registry: SGLT2-I AMI PROTECT. ClinicalTrials.gov Identifier: NCT05261867. [Display omitted] •Multicenter international registry of diabetic AMI patients undergoing PCI divided into SGLT-I users versus non-SGLT2-I users.•A mitigated negative LV remodeling was detected in patients treated with SGLT2-I.•SGLT2-I were associated with a lower in-hospital cardiovascular death and arrhythmic burden.•In SGLT2-I users cardiovascular mortality, HF hospitalization and MACE were significantly lower compared to no-SGLT2-I patients.
AbstractList	To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users). In this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. The primary endpoint was defined as a composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE). Secondary outcomes included i) in-hospital cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI); ii) long-term cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization. The study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p < 0.05). During a median follow-up of 24 ± 13 months, the primary composite endpoint, as well as cardiovascular mortality and HF hospitalization were lower for SGLT2-I users compared to non-SGLT2-I patients (p < 0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of reduced MACE occurrence (HR=0.57; 95%CI:0.33-0.99; p = 0.039) and HF hospitalization (HR=0.46; 95%CI:0.21-0.98; p = 0.041). In T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI. Data are part of the observational international registry: SGLT2-I AMI PROTECT. gov Identifier: NCT05261867. To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users).AIMSTo investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users).In this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. The primary endpoint was defined as a composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE). Secondary outcomes included i) in-hospital cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI); ii) long-term cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization.METHODSIn this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. The primary endpoint was defined as a composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE). Secondary outcomes included i) in-hospital cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI); ii) long-term cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization.The study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p < 0.05). During a median follow-up of 24 ± 13 months, the primary composite endpoint, as well as cardiovascular mortality and HF hospitalization were lower for SGLT2-I users compared to non-SGLT2-I patients (p < 0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of reduced MACE occurrence (HR=0.57; 95%CI:0.33-0.99; p = 0.039) and HF hospitalization (HR=0.46; 95%CI:0.21-0.98; p = 0.041).RESULTSThe study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p < 0.05). During a median follow-up of 24 ± 13 months, the primary composite endpoint, as well as cardiovascular mortality and HF hospitalization were lower for SGLT2-I users compared to non-SGLT2-I patients (p < 0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of reduced MACE occurrence (HR=0.57; 95%CI:0.33-0.99; p = 0.039) and HF hospitalization (HR=0.46; 95%CI:0.21-0.98; p = 0.041).In T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI.CONCLUSIONSIn T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI.Data are part of the observational international registry: SGLT2-I AMI PROTECT.REGISTRATIONData are part of the observational international registry: SGLT2-I AMI PROTECT.gov Identifier: NCT05261867.CLINICALTRIALSgov Identifier: NCT05261867. To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users). In this multicenter international registry all consecutive diabetic AMI patients undergoing percutaneous coronary intervention between 2018 and 2021 were enrolled and, based on the admission anti-diabetic therapy, divided into SGLT-I users versus non-SGLT2-I users. The primary endpoint was defined as a composite of cardiovascular death, recurrent AMI, and hospitalization for HF (MACE). Secondary outcomes included i) in-hospital cardiovascular death, recurrent AMI, occurrence of arrhythmias, and contrast-induced acute kidney injury (CI-AKI); ii) long-term cardiovascular mortality, recurrent AMI, heart failure (HF) hospitalization. The study population consisted of 646 AMI patients (with or without ST-segment elevation): 111 SGLT2-I users and 535 non-SGLT-I users. The use of SGLT2-I was associated with a significantly lower in-hospital cardiovascular death, arrhythmic burden, and occurrence of CI-AKI (all p < 0.05). During a median follow-up of 24 ± 13 months, the primary composite endpoint, as well as cardiovascular mortality and HF hospitalization were lower for SGLT2-I users compared to non-SGLT2-I patients (p < 0.04 for all). After adjusting for confounding factors, the use of SGLT2-I was identified as independent predictor of reduced MACE occurrence (HR=0.57; 95%CI:0.33–0.99; p = 0.039) and HF hospitalization (HR=0.46; 95%CI:0.21–0.98; p = 0.041). In T2DM AMI patients, the use of SGLT2-I was associated with a lower risk of adverse cardiovascular outcomes during index hospitalization and long-term follow-up. Our findings provide new insights into the cardioprotective effects of SGLT2-I in the setting of AMI. Data are part of the observational international registry: SGLT2-I AMI PROTECT. ClinicalTrials.gov Identifier: NCT05261867. [Display omitted] •Multicenter international registry of diabetic AMI patients undergoing PCI divided into SGLT-I users versus non-SGLT2-I users.•A mitigated negative LV remodeling was detected in patients treated with SGLT2-I.•SGLT2-I were associated with a lower in-hospital cardiovascular death and arrhythmic burden.•In SGLT2-I users cardiovascular mortality, HF hospitalization and MACE were significantly lower compared to no-SGLT2-I patients.
ArticleNumber	106597
Author	Santulli, Gaetano Mauro, Ciro Esposito, Giuseppe Gragnano, Felice Cesaro, Arturo Marfella, Raffaele Foà, Alberto Morici, Nuccia Andrea, Oreglia Jacopo Casella, Gianni Sansonetti, Angelo Mileva, Niya Impellizzeri, Andrea Amicone, Sara Gallinoro, Emanuele Barbato, Emanuele Sardu, Celestino Pizzi, Carmine Galie, Nazzareno Bergamaschi, Luca Armillotta, Matteo Paolisso, Pasquale Vassilev, Dobrin Calabrò, Paolo
AuthorAffiliation	f Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy d Department of Translational Medical Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy i IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy c Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant’Orsola-Malpighi Hospital, IRCCS, Bologna, Italy m International Translational Research and Medical Education (ITME) Consortium, Naples, Italy g Cardiology Clinic, “Alexandrovska” University Hospital, Medical University of Sofia, Sofia, Bulgaria n Department of Medicine (Division of Cardiology) and Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein-Sinai Diabetes Research Center, The Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, New York, USA a Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium j Unit
AuthorAffiliation_xml	– name: j Unit of Cardiology, Maggiore Hospital, Bologna, Italy – name: n Department of Medicine (Division of Cardiology) and Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein-Sinai Diabetes Research Center, The Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, New York, USA – name: d Department of Translational Medical Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy – name: e Division of Cardiology, A.O.R.N. “Sant’Anna e San Sebastiano”, Caserta, Italy – name: o Mediterranea Cardiocentro, Naples, Italy – name: f Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy – name: c Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant’Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – name: m International Translational Research and Medical Education (ITME) Consortium, Naples, Italy – name: g Cardiology Clinic, “Alexandrovska” University Hospital, Medical University of Sofia, Sofia, Bulgaria – name: h Interventional Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy – name: i IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy – name: l Medica Cor Hospital, Russe, Bulgaria – name: k Department of Cardiology, Hospital Cardarelli, Naples, Italy – name: a Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium – name: b Dept. of Advanced Biomedical Sciences, University Federico II, Naples, Italy
Author_xml	– sequence: 1 givenname: Pasquale surname: Paolisso fullname: Paolisso, Pasquale organization: Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium – sequence: 2 givenname: Luca surname: Bergamaschi fullname: Bergamaschi, Luca organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 3 givenname: Felice surname: Gragnano fullname: Gragnano, Felice organization: Department of Translational Medical Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy – sequence: 4 givenname: Emanuele surname: Gallinoro fullname: Gallinoro, Emanuele organization: Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium – sequence: 5 givenname: Arturo surname: Cesaro fullname: Cesaro, Arturo organization: Department of Translational Medical Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy – sequence: 6 givenname: Celestino surname: Sardu fullname: Sardu, Celestino organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy – sequence: 7 givenname: Niya surname: Mileva fullname: Mileva, Niya organization: Cardiology Clinic, "Alexandrovska" University Hospital, Medical University of Sofia, Sofia, Bulgaria – sequence: 8 givenname: Alberto surname: Foà fullname: Foà, Alberto organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 9 givenname: Matteo surname: Armillotta fullname: Armillotta, Matteo organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 10 givenname: Angelo surname: Sansonetti fullname: Sansonetti, Angelo organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 11 givenname: Sara surname: Amicone fullname: Amicone, Sara organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 12 givenname: Andrea surname: Impellizzeri fullname: Impellizzeri, Andrea organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 13 givenname: Giuseppe surname: Esposito fullname: Esposito, Giuseppe organization: Dept. of Advanced Biomedical Sciences, University Federico II, Naples, Italy – sequence: 14 givenname: Nuccia surname: Morici fullname: Morici, Nuccia organization: IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy – sequence: 15 givenname: Oreglia Jacopo surname: Andrea fullname: Andrea, Oreglia Jacopo organization: Interventional Cardiology Unit, De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy – sequence: 16 givenname: Gianni surname: Casella fullname: Casella, Gianni organization: Unit of Cardiology, Maggiore Hospital, Bologna, Italy – sequence: 17 givenname: Ciro surname: Mauro fullname: Mauro, Ciro organization: Department of Cardiology, Hospital Cardarelli, Naples, Italy – sequence: 18 givenname: Dobrin surname: Vassilev fullname: Vassilev, Dobrin organization: Medica Cor Hospital, Russe, Bulgaria – sequence: 19 givenname: Nazzareno surname: Galie fullname: Galie, Nazzareno organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 20 givenname: Gaetano surname: Santulli fullname: Santulli, Gaetano organization: Dept. of Advanced Biomedical Sciences, University Federico II, Naples, Italy – sequence: 21 givenname: Raffaele surname: Marfella fullname: Marfella, Raffaele organization: Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy – sequence: 22 givenname: Paolo surname: Calabrò fullname: Calabrò, Paolo organization: Department of Translational Medical Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy – sequence: 23 givenname: Carmine surname: Pizzi fullname: Pizzi, Carmine email: carmine.pizzi@unibo.it organization: Unit of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Sant'Orsola-Malpighi Hospital, IRCCS, Bologna, Italy – sequence: 24 givenname: Emanuele surname: Barbato fullname: Barbato, Emanuele email: emanuele.barbato@olvz-aalst.be organization: Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36470546$$D View this record in MEDLINE/PubMed
BookMark	eNp9kc2O0zAUhSM0iPmBF2CBvGSTYqe2kyCENKqGoVJRR0NYWzfOTeMqjYvtzKgPwTvjKlMELGZl6_qc78j3XCZngx0wSd4yOmOUyQ_b2b5zfpbRLIsDKcr8RXLBaClTxgp5drzzeSolK86TS--3lNKSM_oqOZ9LnlPB5UXyaz0GbXfoiRlIY6DGYDTZQzA4BE-CQwjYkEcTOvL9dlVl6XLoTG2CdX6agh4Dkt3BanAR0EdQC04HYwcyDg26jTXDhtwtlh9J1eGJQq6_Lcnd_bq6WVTkHjfGB3d4nbxsoff45um8Sn58uakWX9PV-na5uF6lmgsRUihqYJKKDDUFQWso5gJqzRBLWkLOeVtyQaHNawFzkCBy5EILSSVvKG2b-VXyeeLux3qHjY5_ddCrvTM7cAdlwah_XwbTqY19UGXJZZ7zCHj_BHD254g-qJ3xGvseBrSjV1nO8ywvmCyj9N3fWX9CTh1EQTEJtLPeO2yVNgGO-4vRpleMqmPdaquOdatj3WqqO1qz_6wn-rOmT5MJ44YfDDrldWxbY2Mc6qAaa56z_wYnpcUu
CitedBy_id	crossref_primary_10_7759_cureus_62978 crossref_primary_10_1038_s41598_024_52375_y crossref_primary_10_1038_s41598_024_67195_3 crossref_primary_10_1177_02676591241257371 crossref_primary_10_1177_00033197251365016 crossref_primary_10_1177_00033197231197230 crossref_primary_10_1186_s12872_023_03099_w crossref_primary_10_1007_s44411_025_00358_4 crossref_primary_10_1186_s12933_024_02181_7 crossref_primary_10_1080_13543784_2023_2263354 crossref_primary_10_1186_s12872_023_03353_1 crossref_primary_10_1093_ehjcvp_pvaf026 crossref_primary_10_17925_HI_2023_17_2_12 crossref_primary_10_1016_j_tcm_2023_12_006 crossref_primary_10_1186_s12933_025_02777_7 crossref_primary_10_3389_fendo_2023_1258766 crossref_primary_10_1053_j_jvca_2024_06_039 crossref_primary_10_1080_14796678_2024_2433381 crossref_primary_10_7759_cureus_60086 crossref_primary_10_1007_s40256_025_00759_4 crossref_primary_10_3390_jcm12165218 crossref_primary_10_1007_s40256_024_00662_4 crossref_primary_10_1097_MJT_0000000000001907 crossref_primary_10_1007_s12265_023_10415_4 crossref_primary_10_1007_s13300_023_01454_w crossref_primary_10_1007_s40256_024_00680_2 crossref_primary_10_1016_j_ajpc_2025_101061 crossref_primary_10_1097_FJC_0000000000001576 crossref_primary_10_1038_s41598_025_01405_4 crossref_primary_10_1007_s12265_024_10513_x crossref_primary_10_1002_ejhf_3566 crossref_primary_10_1097_MD_0000000000043236 crossref_primary_10_1007_s00228_024_03799_y crossref_primary_10_1016_j_hrtlng_2025_05_020 crossref_primary_10_3390_diabetology6080078 crossref_primary_10_3390_ph18081202 crossref_primary_10_3390_jcm12237311 crossref_primary_10_3390_life13112226 crossref_primary_10_3389_fcvm_2023_1280547 crossref_primary_10_3389_fmed_2025_1629369 crossref_primary_10_3390_ijms252111458 crossref_primary_10_3390_medicina59030505 crossref_primary_10_1038_s41598_023_48678_1 crossref_primary_10_2174_0113816128304097240529053538 crossref_primary_10_3389_fendo_2023_1307715 crossref_primary_10_3389_fcvm_2023_1275713 crossref_primary_10_1177_10742484241252474 crossref_primary_10_3389_fendo_2023_1199960 crossref_primary_10_1186_s13063_025_08956_x crossref_primary_10_29333_ejgm_13182 crossref_primary_10_3390_ijms26104494 crossref_primary_10_3390_jcm12072524 crossref_primary_10_1002_ehf2_14790 crossref_primary_10_1093_ehjcvp_pvaf040 crossref_primary_10_1186_s12933_023_01844_1 crossref_primary_10_1016_j_jacadv_2025_101887 crossref_primary_10_1016_j_pharmthera_2025_108861 crossref_primary_10_3390_ijms251910759 crossref_primary_10_3389_fendo_2025_1586541 crossref_primary_10_3390_ph18060857 crossref_primary_10_17925_HI_2023_17_2_5 crossref_primary_10_3389_fendo_2025_1594861 crossref_primary_10_1016_j_ajpc_2024_100927 crossref_primary_10_1186_s12933_023_02118_6 crossref_primary_10_1080_14656566_2024_2418414 crossref_primary_10_1016_j_diabres_2024_111122 crossref_primary_10_1186_s12933_025_02678_9 crossref_primary_10_1186_s12944_023_01790_7 crossref_primary_10_3389_fcvm_2024_1371606 crossref_primary_10_1371_journal_pone_0326534 crossref_primary_10_36516_jocass_1654263 crossref_primary_10_1007_s40256_023_00618_0 crossref_primary_10_1016_j_jdiacomp_2024_108895 crossref_primary_10_1016_j_jdiacomp_2024_108850 crossref_primary_10_1038_s41598_024_81954_2 crossref_primary_10_1177_10742484241301191 crossref_primary_10_1016_j_diabres_2025_112320 crossref_primary_10_1002_ejhf_3145 crossref_primary_10_1080_17512433_2024_2390921 crossref_primary_10_1111_echo_15854 crossref_primary_10_1016_j_clinthera_2024_06_010 crossref_primary_10_1186_s12933_023_02061_6 crossref_primary_10_1007_s10557_025_07716_y crossref_primary_10_1111_dom_16122 crossref_primary_10_1186_s12933_023_02000_5
Cites_doi	10.2337/db15-1356 10.1161/01.CIR.103.13.1759 10.1016/j.phrs.2021.105530 10.1530/JOE-17-0457 10.1186/s12933-020-01127-z 10.1093/ehjcvp/pvab039 10.1056/NEJMoa1911303 10.1016/j.metabol.2021.154936 10.1016/j.mvr.2021.104268 10.1056/NEJMoa2107038 10.1161/CIRCULATIONAHA.121.053350 10.1056/NEJMoa1504720 10.1016/j.jacc.2019.11.031 10.1016/j.freeradbiomed.2017.01.035 10.1093/eurheartj/ehn096 10.1093/eurheartj/eht090 10.1016/j.bbadis.2020.165770 10.1038/s41467-020-15983-6 10.1186/s12933-020-01066-9 10.1007/s00125-020-05359-2 10.1002/jcp.30727 10.1177/2042018820911803 10.1186/s12933-022-01508-6 10.1016/j.jacbts.2018.10.002 10.1016/j.jacc.2022.03.353 10.1056/NEJMoa1611925 10.1186/s12933-021-01384-6 10.1016/j.phrs.2022.106243 10.1186/s12933-022-01506-8 10.1016/j.phrs.2022.106448 10.1161/hyp.79.suppl_1.A1 10.1093/eurheartj/ehac494 10.3389/fcvm.2022.1012220 10.1016/j.ahj.2022.05.010 10.1093/eurheartj/ehac223 10.1016/j.jacc.2019.01.056 10.1016/j.phrs.2020.104870 10.1016/j.jacc.2016.01.069 10.1186/s12933-021-01222-9 10.1161/CIRCIMAGING.116.004841 10.1007/s10741-010-9177-3
ContentType	Journal Article
Copyright	2023 The Authors Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Copyright_xml	– notice: 2023 The Authors – notice: Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM
DOI	10.1016/j.phrs.2022.106597
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1096-1186
EndPage	106597
ExternalDocumentID	PMC9946774 36470546 10_1016_j_phrs_2022_106597 S1043661822005436
Genre	Research Support, Non-U.S. Gov't Multicenter Study Journal Article
GrantInformation_xml	– fundername: NHLBI NIH HHS grantid: R01 HL146691 – fundername: NIDDK NIH HHS grantid: R01 DK123259 – fundername: NIDDK NIH HHS grantid: P30 DK020541
GroupedDBID	--- --K --M .GJ .~1 0R~ 0SF 0ZK 123 1B1 1RT 1~. 1~5 29O 3O- 4.4 457 4G. 53G 5RE 5VS 6I. 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXUO ABFNM ABFRF ABJNI ABMAC ABOCM ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CAG COF CS3 DM4 DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA GROUPED_DOAJ HMT HVGLF HX~ HZ~ IHE J1W KOM L7B LG5 M33 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SPT SSP SSZ T5K TEORI UNMZH WUQ XPP ZA5 ZU3 ZXP ~G- 9DU AATTM AAXKI AAYWO AAYXX ABWVN ACLOT ACRPL ACVFH ADCNI ADNMO ADVLN AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8 5PM
ID	FETCH-LOGICAL-c455t-a8ba16052ec0a50ba835abc1ee909a744f9450af7b5a3a6a57e45c56064d00fd3
ISICitedReferencesCount	106
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000907771000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1043-6618 1096-1186
IngestDate	Tue Sep 30 17:17:21 EDT 2025 Sun Sep 28 06:38:18 EDT 2025 Thu Apr 03 06:57:01 EDT 2025 Sat Nov 29 07:08:06 EST 2025 Tue Nov 18 20:42:58 EST 2025 Fri Feb 23 02:38:37 EST 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Keywords	NSTEMI T2DM HF hospitalization Outcomes SGLT2-I OAD PCI STEMI CABG Acute myocardial infarction AMI HF Arrhythmias RWMA
Language	English
License	This is an open access article under the CC BY-NC-ND license. Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c455t-a8ba16052ec0a50ba835abc1ee909a744f9450af7b5a3a6a57e45c56064d00fd3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The first two authors contributed equally to this work. The last two authors contributed equally to this work. PP and LB contributed conception and design of the study; PP, LB, AC, NM, FG, MA, AS, AS, GE and AI organized the database and collected data; LB and EG performed the statistical analysis; PP and LB wrote the first draft of the manuscript; FG and AC wrote sections of the manuscript. GS, CS, AF, GC, CM, RM, NM, JAO, DV, PC, EB and CP revised the article and approved the final version of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version. Author contributions
OpenAccessLink	http://dx.doi.org/10.1016/j.phrs.2022.106597
PMID	36470546
PQID	2747278169
PQPubID	23479
PageCount	1
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_9946774 proquest_miscellaneous_2747278169 pubmed_primary_36470546 crossref_citationtrail_10_1016_j_phrs_2022_106597 crossref_primary_10_1016_j_phrs_2022_106597 elsevier_sciencedirect_doi_10_1016_j_phrs_2022_106597
PublicationCentury	2000
PublicationDate	2023-01-01
PublicationDateYYYYMMDD	2023-01-01
PublicationDate_xml	– month: 01 year: 2023 text: 2023-01-01 day: 01
PublicationDecade	2020
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	Pharmacological research
PublicationTitleAlternate	Pharmacol Res
PublicationYear	2023
Publisher	Elsevier Ltd
Publisher_xml	– name: Elsevier Ltd
References	Mascolo, Scavone, Scisciola, Chiodini, Capuano, Paolisso (bib16) 2021; 172 Kim, Lee, Kim (bib31) 2020; 11 Ciardullo, Trevisan, Perseghin (bib17) 2021; 166 Lim, Bell, Arjun, Kolatsi-Joannou, Long, Yellon (bib38) 2019; 4 Andreadou, Bell, Bøtker, Zuurbier (bib6) 2020; 1866 von Lewinski, Kolesnik, Tripolt (bib9) 2022 Jelani, Jugdutt (bib23) 2010; 15 Harrington, Udell, Jones (bib8) 2022; 253 Zhong, Yu, Li, Zhou, Wang (bib30) 2022; 139 Marfella, Scisciola, D'Onofrio (bib18) 2022; 184 Zelniker, Braunwald (bib33) 2020; 75 Sayour, Celeng, Oláh, Ruppert, Merkely, Radovits (bib36) 2021; 64 Paolisso, Foà, Bergamaschi (bib29) 2021; 20 Collet, Thiele, Barbato (bib13) 2020; 2021 Tanajak, Sa-Nguanmoo, Sivasinprasasn (bib35) 2018; 236 Santos-Gallego, Requena-Ibanez, San Antonio (bib39) 2019; 73 Fröhlich, Meier, White, Yellon, Hausenloy (bib22) 2013; 34 Suzuki, Kaneko, Okada (bib47) 2022; 21 Lahnwong, Palee, Apaijai (bib7) 2020; 19 Cesaro, Gragnano, Paolisso (bib11) 2022; 9 Manolis, Manolis, Melita, Manolis (bib42) 2022 Philippaert, Kalyaanamoorthy, Fatehi (bib44) 2021; 143 Varzideh, Kansakar, Santulli (bib3) 2021; 7 Frantz, Hundertmark, Schulz-Menger, Bengel, Bauersachs (bib25) 2022 Ferrannini, Baldi, Frascerra (bib32) 2016; 65 Paolisso, Bergamaschi, Santulli (bib10) 2022; 21 Lee, Chang, Lin (bib37) 2017; 104 Ibanez, James, Agewall (bib14) 2017; 2018 Stone, Selker, Thiele (bib21) 2016; 67 Udell, Jones, Petrie (bib1) 2022; 79 Attachaipanich, Chattipakorn, Chattipakorn (bib43) 2022; 237 Mone P., Varzideh F., Jankauskas S.S. et al., SGLT2 inhibition via empagliflozin Improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients, Hypertension 2022. Anker, Butler, Filippatos (bib2) 2021; 385 Hicks, Mahaffey, Mehran (bib15) 2017; 2018 Torabi, Cleland, Khan (bib20) 2008; 29 Neal, Perkovic, Mahaffey (bib19) 2017; 377 Koyani, Plastira, Sourij (bib27) 2020; 158 Paolisso, Foà, Bergamaschi (bib28) 2021; 20 Theofilis, Antonopoulos, Katsimichas (bib24) 2022; 180 Andersen, Jørgensen, Knop, Vilsbøll (bib46) 2020; 11 Zinman, Wanner, Lachin (bib4) 2015; 373 Marfella, D'Onofrio, Trotta (bib12) 2022; 127 Buse, Wexler, Tsapas (bib34) 2019; 2020 Nishino, Watanabe, Kimura (bib41) 2016; 9 McMurray, Solomon, Inzucchi (bib5) 2019; 381 Grigioni, Enriquez-Sarano, Zehr, Bailey, Tajik (bib40) 2001; 103 Shimizu, Kubota, Hoshika (bib45) 2020; 19 Paolisso (10.1016/j.phrs.2022.106597_bib29) 2021; 20 Ferrannini (10.1016/j.phrs.2022.106597_bib32) 2016; 65 von Lewinski (10.1016/j.phrs.2022.106597_bib9) 2022 Santos-Gallego (10.1016/j.phrs.2022.106597_bib39) 2019; 73 Paolisso (10.1016/j.phrs.2022.106597_bib10) 2022; 21 Jelani (10.1016/j.phrs.2022.106597_bib23) 2010; 15 Suzuki (10.1016/j.phrs.2022.106597_bib47) 2022; 21 McMurray (10.1016/j.phrs.2022.106597_bib5) 2019; 381 Neal (10.1016/j.phrs.2022.106597_bib19) 2017; 377 Sayour (10.1016/j.phrs.2022.106597_bib36) 2021; 64 Torabi (10.1016/j.phrs.2022.106597_bib20) 2008; 29 Andersen (10.1016/j.phrs.2022.106597_bib46) 2020; 11 Udell (10.1016/j.phrs.2022.106597_bib1) 2022; 79 Nishino (10.1016/j.phrs.2022.106597_bib41) 2016; 9 Marfella (10.1016/j.phrs.2022.106597_bib12) 2022; 127 Grigioni (10.1016/j.phrs.2022.106597_bib40) 2001; 103 Shimizu (10.1016/j.phrs.2022.106597_bib45) 2020; 19 Anker (10.1016/j.phrs.2022.106597_bib2) 2021; 385 Zinman (10.1016/j.phrs.2022.106597_bib4) 2015; 373 Koyani (10.1016/j.phrs.2022.106597_bib27) 2020; 158 Tanajak (10.1016/j.phrs.2022.106597_bib35) 2018; 236 Cesaro (10.1016/j.phrs.2022.106597_bib11) 2022; 9 Mascolo (10.1016/j.phrs.2022.106597_bib16) 2021; 172 Hicks (10.1016/j.phrs.2022.106597_bib15) 2017; 2018 Fröhlich (10.1016/j.phrs.2022.106597_bib22) 2013; 34 Frantz (10.1016/j.phrs.2022.106597_bib25) 2022 Zhong (10.1016/j.phrs.2022.106597_bib30) 2022; 139 Collet (10.1016/j.phrs.2022.106597_bib13) 2020; 2021 Andreadou (10.1016/j.phrs.2022.106597_bib6) 2020; 1866 Lahnwong (10.1016/j.phrs.2022.106597_bib7) 2020; 19 Paolisso (10.1016/j.phrs.2022.106597_bib28) 2021; 20 Manolis (10.1016/j.phrs.2022.106597_bib42) 2022 Lee (10.1016/j.phrs.2022.106597_bib37) 2017; 104 Harrington (10.1016/j.phrs.2022.106597_bib8) 2022; 253 Kim (10.1016/j.phrs.2022.106597_bib31) 2020; 11 Lim (10.1016/j.phrs.2022.106597_bib38) 2019; 4 Ciardullo (10.1016/j.phrs.2022.106597_bib17) 2021; 166 10.1016/j.phrs.2022.106597_bib26 Buse (10.1016/j.phrs.2022.106597_bib34) 2019; 2020 Varzideh (10.1016/j.phrs.2022.106597_bib3) 2021; 7 Philippaert (10.1016/j.phrs.2022.106597_bib44) 2021; 143 Attachaipanich (10.1016/j.phrs.2022.106597_bib43) 2022; 237 Ibanez (10.1016/j.phrs.2022.106597_bib14) 2017; 2018 Zelniker (10.1016/j.phrs.2022.106597_bib33) 2020; 75 Theofilis (10.1016/j.phrs.2022.106597_bib24) 2022; 180 Stone (10.1016/j.phrs.2022.106597_bib21) 2016; 67 Marfella (10.1016/j.phrs.2022.106597_bib18) 2022; 184
References_xml	– volume: 20 start-page: 192 year: 2021 ident: bib28 article-title: Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA publication-title: Cardiovasc Diabetol. – volume: 236 start-page: 69 year: 2018 end-page: 84 ident: bib35 article-title: Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury publication-title: J. Endocrinol. – year: 2022 ident: bib25 article-title: Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies publication-title: Eur. Heart J. – volume: 64 start-page: 737 year: 2021 end-page: 748 ident: bib36 article-title: Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis publication-title: Diabetologia – volume: 104 start-page: 298 year: 2017 end-page: 310 ident: bib37 article-title: Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts publication-title: Free Radic. Biol. Med. – volume: 75 start-page: 422 year: 2020 end-page: 434 ident: bib33 article-title: Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review publication-title: J. Am. Coll. Cardiol. – volume: 79 start-page: 2058 year: 2022 end-page: 2068 ident: bib1 article-title: Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week publication-title: J. Am. Coll. Cardiol. – volume: 180 year: 2022 ident: bib24 article-title: The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis publication-title: Pharmacol. Res. – volume: 103 start-page: 1759 year: 2001 end-page: 1764 ident: bib40 article-title: Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment publication-title: Circulation – volume: 21 start-page: 77 year: 2022 ident: bib10 article-title: Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry publication-title: Cardiovasc Diabetol. – volume: 11 start-page: 2127 year: 2020 ident: bib31 article-title: SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease publication-title: Nat. Commun. – volume: 1866 year: 2020 ident: bib6 article-title: SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models publication-title: Biochim Biophys. Acta Mol. Basis Dis. – volume: 172 year: 2021 ident: bib16 article-title: SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies publication-title: Pharmacol. Res. – volume: 166 year: 2021 ident: bib17 article-title: Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines publication-title: Pharmacol. Res. – volume: 65 start-page: 1190 year: 2016 end-page: 1195 ident: bib32 article-title: Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 publication-title: Diabetes Diabetes – volume: 2021 start-page: 1289 year: 2020 end-page: 1367 ident: bib13 article-title: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation publication-title: Eur. Heart J. – volume: 237 start-page: 2404 year: 2022 end-page: 2419 ident: bib43 article-title: Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure publication-title: J. Cell Physiol. – volume: 9 year: 2016 ident: bib41 article-title: The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term follow-up publication-title: Circ. Cardiovasc Imaging – volume: 381 start-page: 1995 year: 2019 end-page: 2008 ident: bib5 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction publication-title: N. Engl. J. Med. – reference: Mone P., Varzideh F., Jankauskas S.S. et al., SGLT2 inhibition via empagliflozin Improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients, Hypertension 2022. – volume: 2020 start-page: 221 year: 2019 end-page: 228 ident: bib34 article-title: Update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetologia – volume: 184 year: 2022 ident: bib18 article-title: Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes publication-title: Pharmacol. Res. – volume: 19 start-page: 91 year: 2020 ident: bib7 article-title: Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury publication-title: Cardiovasc Diabetol. – volume: 253 start-page: 86 year: 2022 end-page: 98 ident: bib8 article-title: Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial publication-title: Am. Heart J. – volume: 158 year: 2020 ident: bib27 article-title: Empagliflozin protects heart from inflammation and energy depletion via AMPK activation publication-title: Pharmacol. Res. – volume: 143 start-page: 2188 year: 2021 end-page: 2204 ident: bib44 article-title: Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin publication-title: Circulation – volume: 377 start-page: 644 year: 2017 end-page: 657 ident: bib19 article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes publication-title: N. Engl. J. Med. – volume: 29 start-page: 859 year: 2008 end-page: 870 ident: bib20 article-title: The timing of development and subsequent clinical course of heart failure after a myocardial infarction publication-title: Eur. Heart J. – year: 2022 ident: bib42 article-title: Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias publication-title: Trends Cardiovasc. Med. – volume: 127 year: 2022 ident: bib12 article-title: Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts publication-title: Metabolism – volume: 20 start-page: 33 year: 2021 ident: bib29 article-title: Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA publication-title: Cardiovasc. Diabetol. – volume: 73 start-page: 1931 year: 2019 end-page: 1944 ident: bib39 article-title: Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics publication-title: J. Am. Coll. Cardiol. – volume: 2018 start-page: 119 year: 2017 end-page: 177 ident: bib14 article-title: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) publication-title: Eur. Heart J. – volume: 139 year: 2022 ident: bib30 article-title: Augmented early aged neutrophil infiltration contributes to late remodeling post myocardial infarction publication-title: Microvasc. Res. – volume: 19 start-page: 148 year: 2020 ident: bib45 article-title: Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial publication-title: Cardiovasc. Diabetol. – volume: 9 start-page: 1012220 year: 2022 ident: bib11 article-title: In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: insights from the SGLT2-I AMI PROTECT study publication-title: Front. Cardiovasc. Med. – volume: 67 start-page: 1674 year: 2016 end-page: 1683 ident: bib21 article-title: Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials publication-title: J. Am. Coll. Cardiol. – volume: 7 start-page: e67 year: 2021 end-page: e68 ident: bib3 article-title: SGLT2 inhibitors in cardiovascular medicine publication-title: Eur. Heart J. Cardiovasc. Pharmacother. – volume: 21 start-page: 67 year: 2022 ident: bib47 article-title: Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus publication-title: Cardiovasc. Diabetol. – volume: 373 start-page: 2117 year: 2015 end-page: 2128 ident: bib4 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N. Engl. J. Med. – volume: 15 start-page: 513 year: 2010 end-page: 521 ident: bib23 article-title: STEMI and heart failure in the elderly: role of adverse remodeling publication-title: Heart Fail. Rev. – volume: 11 year: 2020 ident: bib46 article-title: Hypoglycaemia and cardiac arrhythmias in diabetes publication-title: Ther. Adv. Endocrinol. Metab. – year: 2022 ident: bib9 article-title: Empagliflozin in acute Myocardial Infarction: the EMMY trial publication-title: Eur. Heart J. – volume: 34 start-page: 1714 year: 2013 end-page: 1722 ident: bib22 article-title: Myocardial reperfusion injury: looking beyond primary PCI publication-title: Eur. Heart J. – volume: 4 start-page: 15 year: 2019 end-page: 26 ident: bib38 article-title: SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart publication-title: JACC Basic Transl. Sci. – volume: 2018 start-page: 961 year: 2017 end-page: 972 ident: bib15 article-title: Cardiovascular and stroke endpoint definitions for clinical trials publication-title: Circulation – volume: 385 start-page: 1451 year: 2021 end-page: 1461 ident: bib2 article-title: Empagliflozin in heart failure with a preserved ejection fraction publication-title: N. Engl. J. Med. – volume: 172 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib16 article-title: SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies publication-title: Pharmacol. Res. – volume: 65 start-page: 1190 year: 2016 ident: 10.1016/j.phrs.2022.106597_bib32 article-title: Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 publication-title: Diabetes Diabetes doi: 10.2337/db15-1356 – volume: 2018 start-page: 119 issue: 39 year: 2017 ident: 10.1016/j.phrs.2022.106597_bib14 publication-title: Eur. Heart J. – volume: 103 start-page: 1759 year: 2001 ident: 10.1016/j.phrs.2022.106597_bib40 article-title: Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment publication-title: Circulation doi: 10.1161/01.CIR.103.13.1759 – volume: 166 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib17 article-title: Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2021.105530 – volume: 236 start-page: 69 year: 2018 ident: 10.1016/j.phrs.2022.106597_bib35 article-title: Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury publication-title: J. Endocrinol. doi: 10.1530/JOE-17-0457 – volume: 19 start-page: 148 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib45 article-title: Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-020-01127-z – volume: 7 start-page: e67 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib3 article-title: SGLT2 inhibitors in cardiovascular medicine publication-title: Eur. Heart J. Cardiovasc. Pharmacother. doi: 10.1093/ehjcvp/pvab039 – volume: 381 start-page: 1995 year: 2019 ident: 10.1016/j.phrs.2022.106597_bib5 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1911303 – volume: 127 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib12 article-title: Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts publication-title: Metabolism doi: 10.1016/j.metabol.2021.154936 – volume: 2021 start-page: 1289 issue: 42 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib13 article-title: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation publication-title: Eur. Heart J. – volume: 2020 start-page: 221 issue: 63 year: 2019 ident: 10.1016/j.phrs.2022.106597_bib34 article-title: Update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetologia – volume: 139 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib30 article-title: Augmented early aged neutrophil infiltration contributes to late remodeling post myocardial infarction publication-title: Microvasc. Res. doi: 10.1016/j.mvr.2021.104268 – volume: 385 start-page: 1451 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib2 article-title: Empagliflozin in heart failure with a preserved ejection fraction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2107038 – volume: 143 start-page: 2188 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib44 article-title: Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.121.053350 – volume: 373 start-page: 2117 year: 2015 ident: 10.1016/j.phrs.2022.106597_bib4 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504720 – volume: 75 start-page: 422 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib33 article-title: Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2019.11.031 – volume: 104 start-page: 298 year: 2017 ident: 10.1016/j.phrs.2022.106597_bib37 article-title: Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts publication-title: Free Radic. Biol. Med. doi: 10.1016/j.freeradbiomed.2017.01.035 – volume: 29 start-page: 859 year: 2008 ident: 10.1016/j.phrs.2022.106597_bib20 article-title: The timing of development and subsequent clinical course of heart failure after a myocardial infarction publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehn096 – volume: 34 start-page: 1714 year: 2013 ident: 10.1016/j.phrs.2022.106597_bib22 article-title: Myocardial reperfusion injury: looking beyond primary PCI publication-title: Eur. Heart J. doi: 10.1093/eurheartj/eht090 – volume: 1866 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib6 article-title: SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models publication-title: Biochim Biophys. Acta Mol. Basis Dis. doi: 10.1016/j.bbadis.2020.165770 – volume: 11 start-page: 2127 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib31 article-title: SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease publication-title: Nat. Commun. doi: 10.1038/s41467-020-15983-6 – volume: 19 start-page: 91 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib7 article-title: Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury publication-title: Cardiovasc Diabetol. doi: 10.1186/s12933-020-01066-9 – volume: 64 start-page: 737 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib36 article-title: Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis publication-title: Diabetologia doi: 10.1007/s00125-020-05359-2 – volume: 2018 start-page: 961 issue: 137 year: 2017 ident: 10.1016/j.phrs.2022.106597_bib15 article-title: Cardiovascular and stroke endpoint definitions for clinical trials publication-title: Circulation – volume: 237 start-page: 2404 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib43 article-title: Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure publication-title: J. Cell Physiol. doi: 10.1002/jcp.30727 – year: 2022 ident: 10.1016/j.phrs.2022.106597_bib42 article-title: Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias publication-title: Trends Cardiovasc. Med. – volume: 11 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib46 article-title: Hypoglycaemia and cardiac arrhythmias in diabetes publication-title: Ther. Adv. Endocrinol. Metab. doi: 10.1177/2042018820911803 – volume: 21 start-page: 67 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib47 article-title: Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-022-01508-6 – volume: 4 start-page: 15 year: 2019 ident: 10.1016/j.phrs.2022.106597_bib38 article-title: SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart publication-title: JACC Basic Transl. Sci. doi: 10.1016/j.jacbts.2018.10.002 – volume: 79 start-page: 2058 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib1 article-title: Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2022.03.353 – volume: 377 start-page: 644 year: 2017 ident: 10.1016/j.phrs.2022.106597_bib19 article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1611925 – volume: 20 start-page: 192 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib28 article-title: Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA publication-title: Cardiovasc Diabetol. doi: 10.1186/s12933-021-01384-6 – volume: 180 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib24 article-title: The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2022.106243 – volume: 21 start-page: 77 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib10 article-title: Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry publication-title: Cardiovasc Diabetol. doi: 10.1186/s12933-022-01506-8 – volume: 184 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib18 article-title: Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2022.106448 – ident: 10.1016/j.phrs.2022.106597_bib26 doi: 10.1161/hyp.79.suppl_1.A1 – year: 2022 ident: 10.1016/j.phrs.2022.106597_bib9 article-title: Empagliflozin in acute Myocardial Infarction: the EMMY trial publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehac494 – volume: 9 start-page: 1012220 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib11 article-title: In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: insights from the SGLT2-I AMI PROTECT study publication-title: Front. Cardiovasc. Med. doi: 10.3389/fcvm.2022.1012220 – volume: 253 start-page: 86 year: 2022 ident: 10.1016/j.phrs.2022.106597_bib8 article-title: Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial publication-title: Am. Heart J. doi: 10.1016/j.ahj.2022.05.010 – year: 2022 ident: 10.1016/j.phrs.2022.106597_bib25 article-title: Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehac223 – volume: 73 start-page: 1931 year: 2019 ident: 10.1016/j.phrs.2022.106597_bib39 article-title: Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2019.01.056 – volume: 158 year: 2020 ident: 10.1016/j.phrs.2022.106597_bib27 article-title: Empagliflozin protects heart from inflammation and energy depletion via AMPK activation publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2020.104870 – volume: 67 start-page: 1674 year: 2016 ident: 10.1016/j.phrs.2022.106597_bib21 article-title: Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2016.01.069 – volume: 20 start-page: 33 year: 2021 ident: 10.1016/j.phrs.2022.106597_bib29 article-title: Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-021-01222-9 – volume: 9 year: 2016 ident: 10.1016/j.phrs.2022.106597_bib41 article-title: The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term follow-up publication-title: Circ. Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.116.004841 – volume: 15 start-page: 513 year: 2010 ident: 10.1016/j.phrs.2022.106597_bib23 article-title: STEMI and heart failure in the elderly: role of adverse remodeling publication-title: Heart Fail. Rev. doi: 10.1007/s10741-010-9177-3
SSID	ssj0009410
Score	2.6412086
Snippet	To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral...
SourceID	pubmedcentral proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	106597
SubjectTerms	Acute Kidney Injury - etiology Acute myocardial infarction Arrhythmias Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy HF hospitalization Humans Myocardial Infarction - drug therapy Outcomes Percutaneous Coronary Intervention - adverse effects Registries Risk Factors SGLT2-I Sodium-Glucose Transporter 2 Inhibitors - adverse effects Treatment Outcome
Title	Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
URI	https://dx.doi.org/10.1016/j.phrs.2022.106597 https://www.ncbi.nlm.nih.gov/pubmed/36470546 https://www.proquest.com/docview/2747278169 https://pubmed.ncbi.nlm.nih.gov/PMC9946774
Volume	187
WOSCitedRecordID	wos000907771000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: 开放获取期刊（Open Access Journals） customDbUrl: eissn: 1096-1186 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009410 issn: 1043-6618 databaseCode: DOA dateStart: 20230101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1096-1186 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009410 issn: 1043-6618 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ1ba9swFIBFL2P0ZezaZZegwehL6-LYsmXtLYQ0y-glsGzkzciOnLokdsmltD9iP3D_Zke3OE1Y2QZ7MUGWZcXns3SOfM4RQh_9SCSuT7jjc99zCI2Iw8GKcMIsGgZJ5mWZ2ovg-yk9P48GA9bb2vppY2FuxrQoottbdv1fRQ1lIGwZOvsX4l42CgXwG4QORxA7HP9I8BeLOTQrtJ-rWlnNU5s-daYdy63L-dfOad9zusVlnuRq1x0d6ZZK34HJHcxyUxVWAr2CZ6RAkSFn01Ep1xd6ra512TDtHDbPuiDSi3671Qe5jdRGcqvab6_Kk63YMJmGlivSPV6OAYRSq7YzGfBZffSH-_IJB2Ncx3MvKh-jzpSPCq72ED88EeO8grXDZcrxUsfytCe8WAjTolno8PyVhQ49NktHAVAn9HAtTBkLHbCRwvsDOl0ZkhvyyzFdmeCrgo3pQ69kXB3DeyRTuXve8WZleLTXE8WOTL0PGu9aJm-lG_TOWozBHETJNtr1aMBgwN1tdtuDL1VGaGJTZeh_ZSK6tPPhegf20GN7t98pUJsG0rqf74ri1H-KnhiLBzc1qc_QliieowODwt0R7lcRgLMjfIBXILl7gX5YnHFeYIsztjhjgzOW4OJ1nHWpwhlXOOMKZ1zhjAHnT7IvthUMMGMDM7Ywv0TfTtr91mfHbCHipCQI5g6PEt4Ai90TqcsDN-FgcPAkbQjBXMYpIRkjgcszmgTc5yEPqCBBClZASIaumw39V2inKAvxGuEkBWWfCRH5JAEbgkVQyU_pMEyZHH68GmpYucSpya8vt3kZx9aR8iqWYo2lWGMt1ho6XF5zrbPLPFg7sOKOjX6s9d4Y-H3wug-WjRgmD_lFkBeiXEAlSsB-iRohq6F9zcqyH5a3GqL3KFpWkInp758p8kuVoN6g_-afr3yL9qoR4B3amU8X4j16lN7M89m0jrbpIKqb96muVtF-AfSDDIQ
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Outcomes+in+diabetic+patients+treated+with+SGLT2-Inhibitors+with+acute+myocardial+infarction+undergoing+PCI%3A+The+SGLT2-I+AMI+PROTECT+Registry&rft.jtitle=Pharmacological+research&rft.au=Paolisso%2C+Pasquale&rft.au=Bergamaschi%2C+Luca&rft.au=Gragnano%2C+Felice&rft.au=Gallinoro%2C+Emanuele&rft.date=2023-01-01&rft.issn=1043-6618&rft.eissn=1096-1186&rft.volume=187&rft.spage=106597&rft.epage=106597&rft_id=info:doi/10.1016%2Fj.phrs.2022.106597&rft_id=info%3Apmid%2F36470546&rft.externalDocID=PMC9946774
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-6618&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-6618&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-6618&client=summon